These results identify potential targets of COMPASS complexes in bladder cancer that are affected similarly by mutations in KDM6A and KMT2D and provides additional support to previous work showing that KDM6A or KMT2D loss have similar biologic consequences [20, 21]. Here, KMT2D is linked to urinary bladder carcinoma.